Understanding Therapies

Gene Therapy & Treatments

Explore treatment approaches for IRDs including gene therapy, optogenetics, stem cells, and neuroprotection strategies.

Therapy Education

A comprehensive guide to the therapeutic approaches being developed to treat inherited retinal diseases — from gene-specific corrections to gene-agnostic strategies that work regardless of the underlying mutation.

Gene-Specific vs Gene-Agnostic Therapies

One of the most fundamental distinctions in IRD therapy development is whether a treatment targets a specific genetic mutation or works regardless of the underlying cause. This distinction determines which patients can benefit, how broadly the therapy can be applied, and the development pathway required.

Gene-Specific Therapies

These treatments are designed to correct or compensate for a specific genetic defect. They target the root cause of disease in patients with a confirmed mutation in a particular gene.

How They Work

Deliver a functional copy of the defective gene, edit the mutation directly, or modulate the gene's RNA to restore protein function.

Examples

Luxturna (RPE65 gene replacement), EDIT-101 (CEP290 CRISPR editing), Sepofarsen (CEP290 RNA modulation), AAV5-RPGR (RPGR gene replacement)

Advantages

Addresses root cause, potential for long-lasting or permanent correction, can halt or reverse disease progression if delivered early enough.

Limitations

Only benefits patients with that specific mutation, requires genetic testing for eligibility, each gene needs its own therapy development program (expensive and time-consuming).

Gene-Agnostic Therapies

These treatments work regardless of which gene is mutated. They target downstream pathways, replace lost cells, or bypass the natural visual system entirely.

Protect remaining cells from dying, replace dead cells with new ones, make surviving cells light-sensitive, or use electronic devices to stimulate the visual pathway.

Optogenetics (MCO-010), neuroprotective factors (RdCVF), RPE cell transplants (OpRegen), retinal implants (PRIMA), visual cycle modulators (ALK-001)

Can benefit all IRD patients regardless of mutation, larger potential patient population, one therapy can serve many conditions, viable for patients with unknown genetic cause.

Does not fix the underlying genetic defect, may require ongoing treatment, some approaches only work at specific disease stages (e.g., optogenetics requires surviving retinal ganglion cells).

Why Both Approaches Matter

With over 270 genes known to cause IRDs, it is impractical to develop a gene-specific therapy for every mutation. Gene-agnostic approaches ensure that patients with ultra-rare mutations, unknown genetic causes, or advanced disease still have treatment options. Meanwhile, gene-specific therapies offer the best chance of halting disease at its source for patients identified early. The future of IRD treatment likely involves combination approaches — a gene-specific correction paired with neuroprotection, for example.

Early Intervention vs Late-Stage Treatment

The timing of treatment is critical in inherited retinal diseases. Most IRDs involve progressive degeneration — photoreceptor cells die over months to decades, and once lost, they cannot regenerate naturally. This creates a "window of opportunity" where different therapies become relevant at different stages of disease progression.

Disease Progression & Treatment Windows

Early Intervention

Treatment before significant cell loss has occurred. The goal is to prevent degeneration from starting or progressing.

Gene replacement therapy — delivers a working gene before cells die

Neuroprotection — slows or halts the death of photoreceptors

RNA modulation — corrects splicing errors to restore protein production

Gene editing — permanently corrects the DNA mutation in situ

Key requirement: Early genetic diagnosis. Patients must be identified before irreversible damage occurs, making newborn screening and genetic testing critical.

Late-Stage Treatment

Treatment after substantial photoreceptor loss. The goal is to restore some vision or provide alternative visual input.

Optogenetics — makes surviving non-photoreceptor cells light-sensitive

Cell transplantation — replaces dead photoreceptors or RPE cells

Retinal prosthetics — electronic devices that stimulate remaining neurons

Cortical implants — bypass the eye entirely, stimulate visual cortex

Key advantage: Gene-agnostic. These approaches don't require knowing the genetic cause and can help patients regardless of which gene is affected or how far disease has progressed.

The Importance of Genetic Testing

Early genetic diagnosis is the single most important factor in determining treatment options. Patients diagnosed early with a known mutation have access to gene-specific therapies that can prevent vision loss entirely. Those diagnosed later may still benefit from gene-agnostic approaches. Every IRD patient should pursue genetic testing — even if no treatment is available today, knowing the mutation prepares them for future clinical trials and emerging therapies.

Therapeutic Modalities

Multiple distinct therapeutic approaches are being developed for IRDs, each with different mechanisms, delivery methods, and applicability. Here is a detailed look at each major modality.

Gene Replacement Therapy

Gene replacement therapy delivers a functional copy of a defective gene into target retinal cells using a viral vector (typically adeno-associated virus, or AAV). The healthy gene produces the missing protein, restoring cellular function. This is the most advanced IRD therapy approach, with Luxturna as the first FDA-approved example.

How It's Delivered

Subretinal injection: Surgeon lifts the retina and injects vector beneath it, directly targeting photoreceptors and RPE cells. Requires vitrectomy surgery.

Intravitreal injection: Injected into the vitreous cavity (less invasive). Newer AAV variants (AAV44.9, 4D-R100) are being engineered to reach the retina from the vitreous.

Key Considerations

• AAV vectors have a ~4.7 kb packaging limit (some genes are too large)

• Immune response to the vector can limit re-dosing

• Requires viable target cells — less effective in advanced disease

• One-time treatment with potential for durable effect

• Each gene requires its own vector construct and clinical program

Current landscape: Luxturna (RPE65) is FDA-approved. 15+ gene therapies are in clinical trials targeting RPGR, CNGA3, CNGB3, RS1, ABCA4 (dual-vector), CHM, PDE6B, MERTK, and others. View full pipeline →

Gene Editing (CRISPR & Beyond)

Rather than adding a new gene, gene editing directly corrects the mutation in the patient's own DNA. CRISPR-Cas9 is the most well-known system, but newer approaches like base editing and prime editing offer greater precision with fewer off-target effects.

CRISPR-Cas9

Creates a double-strand break at the target site. Can delete, disrupt, or replace DNA sequences. Used in EDIT-101 (Editas Medicine) for CEP290 mutations causing LCA10.

Base Editing

Converts one DNA base to another without cutting both strands. Ideal for point mutations. No double-strand breaks means fewer off-target insertions/deletions.

Prime Editing

"Search and replace" for DNA — can make any small edit (insertions, deletions, all 12 base-to-base conversions) without double-strand breaks. Most versatile but still early-stage.

Advantage over gene replacement: Gene editing can handle genes too large for AAV packaging (like ABCA4 at 6.8 kb and USH2A at 15.6 kb) by correcting the mutation in place rather than delivering the entire gene. It also preserves natural gene regulation.

RNA Therapies

RNA-based therapies work at the messenger RNA level — after DNA is transcribed but before protein is made. They can correct splicing errors, reduce toxic protein production, or supply missing mRNA directly. Unlike gene therapy, RNA treatments are typically reversible and can be re-dosed.

Antisense Oligonucleotides (ASOs)

Short synthetic RNA strands that bind to pre-mRNA to correct aberrant splicing. Sepofarsen targets the CEP290 c.2991+1655A>G intronic mutation (most common LCA10 cause), redirecting splicing to produce functional protein.

RNA Interference (RNAi/siRNA)

Silences expression of toxic gain-of-function genes. Useful for dominant mutations where the mutant protein itself causes damage (e.g., some forms of rhodopsin-related RP where the misfolded protein is toxic).

mRNA Therapy

Delivers synthetic mRNA encoding the missing protein, packaged in lipid nanoparticles. Does not alter DNA. Requires repeated dosing but avoids immune responses to viral vectors. Early-stage research for retinal applications.

Key advantage: RNA therapies require periodic re-dosing (typically intravitreal injections every few months), but this also means the dose can be adjusted and treatment can be stopped if side effects occur. They also bypass the AAV packaging size limit.

Optogenetics

Optogenetics introduces light-sensitive proteins (opsins) into surviving retinal cells that are not normally photosensitive — typically retinal ganglion cells or bipolar cells. This effectively creates new "photoreceptors" from cells that survived the degeneration process, restoring some degree of light perception and pattern vision.

How It Works

An AAV vector delivers a gene encoding a light-sensitive protein (channelrhodopsin, halorhodopsin, or engineered multi-characteristic opsin) to surviving inner retinal cells. When light hits these modified cells, they generate electrical signals that travel to the brain via the optic nerve, creating visual perception.

Current Programs

• MCO-010 (Nanoscope): Multi-characteristic opsin, ambient light levels, Phase 2/3

• GS030 (GenSight): ChrimsonR + light-amplifying goggles, Phase 1/2

• BS01 (Bionic Sight): Optogenetic + neural coding, Phase 1/2

Ideal candidates: Patients with advanced RP or other IRDs who have lost most photoreceptors but retain intact inner retinal layers (ganglion cells and bipolar cells). Does not require knowing the genetic cause — works for any IRD at the appropriate stage.

Neuroprotection

Neuroprotective therapies aim to keep retinal cells alive longer, regardless of the underlying genetic defect. They don't fix the mutation but slow or halt the degeneration process, preserving remaining vision. This approach is particularly valuable because it can benefit patients with any IRD genotype.

Neurotrophic Factors

Rod-derived Cone Viability Factor (RdCVF): A protein naturally secreted by rod photoreceptors that keeps cone cells alive. In RP, rods die first, then cones die from lack of RdCVF. Delivering RdCVF via gene therapy (SparingVision) can preserve central vision even after rods are lost.

CNTF (Ciliary Neurotrophic Factor): Delivered via encapsulated cell implant (NT-501). Provides continuous slow-release neuroprotection to photoreceptors.

Anti-Apoptotic Approaches

Calcium channel blockers: Reduce calcium overload that triggers photoreceptor death.

Autophagy modulators: Enhance cellular cleanup mechanisms to remove toxic protein aggregates.

Anti-oxidants: Reduce oxidative stress damage in degenerating retinas (e.g., N-acetylcysteine amide).

Combination potential: Neuroprotection is often envisioned as a complement to gene-specific therapies. A patient might receive gene therapy to fix the underlying defect while simultaneously receiving neuroprotection to preserve cells during the period before the gene therapy takes full effect.

Cell-Based Therapies

Cell-based therapies replace dead or dying retinal cells with new, healthy cells. This approach is particularly relevant for patients with moderate to advanced disease where significant cell loss has already occurred. The transplanted cells can be derived from embryonic stem cells, induced pluripotent stem cells (iPSCs), or fetal retinal tissue.

RPE Cell Transplants

Replace the retinal pigment epithelium layer that supports photoreceptors. Most advanced approach. OpRegen (Lineage Cell Therapeutics) transplants hESC-derived RPE cells as a suspension or sheet. Particularly relevant for conditions affecting RPE (e.g., geographic atrophy, some forms of RP).

Photoreceptor Replacement

Replace dead photoreceptor cells with new ones derived from stem cells. The transplanted cells must integrate into the existing retinal circuitry and form synaptic connections with bipolar cells. This is technically more challenging than RPE replacement but could restore vision in advanced disease.

Retinal Organoids

3D structures grown from stem cells that mimic the layered architecture of the retina. Can be transplanted as tissue patches rather than individual cells, potentially improving integration. jCyte's jCell product uses retinal progenitor cells that secrete neuroprotective factors.

Key challenges: Ensuring transplanted cells survive, integrate with existing neural circuits, form proper synaptic connections, and avoid immune rejection. Immunosuppression may be required unless using autologous iPSC-derived cells (from the patient's own tissue).

Retinal Implants & Prosthetics

Electronic retinal prostheses bypass damaged photoreceptors entirely, using cameras and microelectrode arrays to directly stimulate surviving retinal neurons or the visual cortex. These devices are designed for patients with end-stage disease who have lost virtually all photoreceptor function.

Types of Implants

Epiretinal: Electrode array placed on the retinal surface (inner limiting membrane). Stimulates ganglion cells directly. Example: Argus II (now discontinued).

Subretinal: Placed between the retina and RPE. Stimulates bipolar cells, leveraging more natural signal processing. Example: PRIMA (Pixium Vision) — wireless, photovoltaic.

Suprachoroidal: Placed between the choroid and sclera. Less invasive surgery but further from target neurons.

Cortical: Bypasses the eye entirely, stimulating the visual cortex directly. For patients with optic nerve damage. Example: Orion (Cortica/Second Sight).

Current State of Technology

Current devices provide low-resolution vision (typically 60–400 electrodes vs. millions of photoreceptors in a healthy eye). Patients can perceive light patterns, detect motion, and navigate environments, but cannot read standard print or recognize faces.

Next generation: Higher electrode density (thousands of pixels), wireless power delivery, AI-enhanced image processing, and materials that better interface with neural tissue are all in development.

Ideal candidates: Patients with bare light perception or total blindness from RP or other IRDs, who retain an intact optic nerve and visual cortex. The retinal implant field has faced commercial challenges (Argus II discontinued, Second Sight bankruptcy) but research continues with newer photovoltaic designs.

Small Molecules & Pharmacological Approaches

Traditional pharmaceutical compounds (pills, eye drops, or injections) that modulate specific biochemical pathways in the retina. These are often easier to manufacture and deliver than biological therapies, and some can be taken orally.

Visual Cycle Modulators

ALK-001 (Gildeuretinol): A modified form of vitamin A that slows the accumulation of toxic lipofuscin (A2E) in RPE cells. Targets Stargardt disease and geographic atrophy. Oral capsule, Phase 3 trial. Works by replacing dietary vitamin A with a form that produces less toxic byproduct.

Complement Inhibitors

Target the complement cascade (part of the immune system) that contributes to retinal cell death in some IRDs and AMD. Pegcetacoplan (Syfovre) is FDA-approved for geographic atrophy. Research is exploring whether complement inhibition can slow degeneration in certain IRDs.

Pharmacological Chaperones

Small molecules that stabilize misfolded proteins, helping them fold correctly and reach their proper cellular location. Relevant for missense mutations where the protein is made but misfolds (e.g., certain rhodopsin mutations in autosomal dominant RP).

Read-Through Agents

Compounds like ataluren (PTC124) that allow ribosomes to "read through" premature stop codons (nonsense mutations), producing full-length functional protein. Applicable to the ~10-15% of IRD patients whose disease is caused by nonsense mutations.

Modality Comparison

The following table summarizes all major therapeutic modalities, comparing their specificity, applicable disease stage, delivery method, and development status.

Modality

Gene-Specific?

Disease Stage

Delivery

Example

Status

The Future: Combination Approaches

The most promising future for IRD treatment likely involves combining multiple modalities to address different aspects of the disease simultaneously. Just as cancer treatment often combines surgery, chemotherapy, and immunotherapy, IRD treatment may combine:

Example Combinations

Gene therapy + Neuroprotection: Fix the genetic defect while protecting remaining cells during the period before gene therapy takes full effect.

Cell therapy + Gene editing: Transplant new cells that have been gene-corrected ex vivo (outside the body) before implantation.

Optogenetics + AI-enhanced prosthetics: Combine biological light sensitivity with electronic signal processing for enhanced visual output.

Small molecules + Gene therapy: Use pharmacological chaperones to stabilize partially functional protein while gene therapy builds up full expression.

Emerging Technologies

AI-designed vectors: Machine learning to engineer AAV capsids with improved retinal targeting and reduced immunogenicity.

Epigenetic therapies: Modifying gene expression without changing DNA sequence — reactivating silenced genes or suppressing toxic ones.

Nanotechnology delivery: Nanoparticle-based delivery systems that can cross biological barriers and target specific cell types without viral vectors.

Bioelectronic medicine: Next-generation neural interfaces with thousands of electrodes and AI processing for near-natural vision restoration.

Explore Active IRD Therapies

See which therapies are currently in development for inherited retinal diseases, from early Phase 1 studies through FDA-approved treatments.

Treatment Pipeline

Track gene therapies and treatments currently in clinical trials for IRDs.

Active Clinical Trials

Browse all active clinical trials for inherited retinal diseases.

Genetic Testing Guide

Understand how genetic testing identifies your specific mutation and treatment options.